Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VECODUE: Vemurafenib and Cobimetinib in Melanoma After Immunotherapy
NCT03224208Phase 2Terminated
- Start
- May 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, cobimetinib in melanoma. Started May 2018; status: terminated.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03224208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224208.